您搜索了: irispigmentering (丹麦语 - 英语)

den øgede irispigmentering er sandsynligvis permanent.
increased iris pigmentation is likely to be permanent.

langtidsvirkningerne af den øgede irispigmentering kendes ikke.
the long term effects of increased iridial pigmentation are not known.

virkninger af øget irispigmentering på lang sigt kendes ikke.
the long term effects of increased iris pigmentation are not known.

astenopi, konjunktivalt ødem, fotofobi, tåreflåd, øget irispigmentering, sløret syn
asthenopia, conjunctival oedema, photophobia, tearing, increased iris pigmentation; blurred vision

efter 12 måneders behandling med ganfort var incidensen af irispigmentering 0,2 %.
after 12 months treatment with ganfort, the incidence of iris pigmentation was 0.2%.

efter at behandlingen er stoppet, er der ikke observeret en stigning i brun irispigmentering.
after discontinuation of therapy, no further increase in brown iris pigment has been observed.

tilsyneladende skyldes stigningen i irispigmentering øget stimulation af melaninproduktion i melanocytter og ikke en stigning i melanocyttallet.
the increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number.

efter 12 måneders behandling med ganfort (flerdosisformulering) var incidensen af irispigmentering 0,2 %.
after 12 months of treatment with ganfort (multi-dose formulation), the incidence of iris pigmentation was 0.2%.

det er sandsynligt, at den øgede irispigmentering vil være permanent og kan medføre forskelle i øjnenes udseende, når kun det ene øje behandles.
increased iris pigmentation is likely to be permanent, and may lead to differences in appearance between the eyes if only one eye is treated.

det er sandsynligt, at den øgede irispigmentering vil være permanent og kan medføre til forskelle i øjnenes udseende, når kun det ene øje behandles.
increased iris pigmentation is likely to be permanent, and may lead to differences in appearance between the eyes if only one eye is treated.

allergisk konjunktivitis, katarakt, mørkfarvning af øjenlåg, øget irispigmentering, blepharospasmus, øjenlågsretraktion, retinal blødning, uveitis.
nervous system disorders: dizziness eye disorders: allergic conjunctivitis, cataract, eyelash darkening, increased iris pigmentation, blepharospasm, eyelid retraction, retinal haemorrhage, uveitis.

før behandlingen påbegyndes, skal patienten oplyses om muligheden for vækst af øjenvipper, mørkfarvning af øjenlågshuden og øget irispigmentering, eftersom dette har været observeret ved behandling med lumigan.
before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation, since these have been observed during treatment with lumigan.

0,3 mg pegaptanib viser behandlingsfordele uanset baseline læsionsundergruppe, læsionsstørrelse og synsskarphed såvel som alder, køn, irispigmentering og tidligere og/eller baseline pdt behandling.
pegaptanib 0.3 mg showed treatment benefit regardless of baseline lesion subtype, lesion size and visual acuity as well as age, gender, iris pigmentation and prior and/or baseline pdt usage.

efter seponering af ganfort kan irispigmenteringen være permanent.
after discontinuation of ganfort, pigmentation of iris may be permanent.